drugset / Trial / NCT03634007
Gene Therapy for APOE4 Homozygote of Alzheimer's Disease
Phase 1/2
Completed
15 enrolled
Lexeo Therapeutics
Alzheimer's Drug Discovery Foundation · collabWeill Medical College of Cornell University · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This clinical trial is an open label, dose-ranging study designed to evaluate gene therapy to treat patients who are APOE4 homozygotes with clinical diagnosis varying from mild cognitive impairment due to Alzheimer's, mild dementia due to Alzheimer's disease, and moderate dementia due to Alzheimer's disease.
Timeline
- Start
- 2019-11-06
- Primary completion
- 2024-11-07
- Completion
- 2024-11-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LX1001 | Gene therapy (AAV / viral vector) | 1.4e+10 vg | Intrathecal |
| Subject | LX1001 | Gene therapy (AAV / viral vector) | 4.4e+10 vg | Intrathecal |
| Subject | LX1001 | Gene therapy (AAV / viral vector) | 1.4e+11 vg | Intrathecal |
| Subject | LX1001 | Gene therapy (AAV / viral vector) | 1.4e+14 vg | Intrathecal |